Targeting two immune pathways eases bacteria-triggered lung injury in mice
en-GBde-DEes-ESfr-FR

Targeting two immune pathways eases bacteria-triggered lung injury in mice

16/11/2026 TranSpread

Previous studies have shown that K. pneumoniae can alter lung metabolism and change how macrophages, immune cells that help clear bacteria, respond to infection. In severe empyema, antibiotics and drainage are central to care, yet inflammation can persist and damage the barrier that normally keeps fluid from leaking into the lung's air sacs. Much of the earlier research examined either the bacterium or the immune response at a single point in time. That left an open question about how inflammation changes during illness and whether blocking multiple signaling pathways could reduce the resulting tissue injury.

A study (DOI: 10.48130/targetome-0026-0055) published in Targetome on 05 November 2026 by Xudong Wu's team, Nanjing University, reports that combined treatment with curcumin and evodiamine reduced signaling through both enzymes and eased lung injury in a mouse model.

The researchers profiled small molecules and measured gene activity in pleural fluid collected over three weeks from one patient with severe K. pneumoniae empyema. The chemical profiles pointed to changes in taurine metabolism, while the gene activity data identified three genes at the center of an inflammation-associated network, MAPK8, JAK2 and TP53. When the team mapped these genes onto publicly available single-cell data from severe lung disease, it found elevated expression in macrophages and in type II alveolar cells, which help maintain the air sacs. Computer simulations that modeled switching off individual genes linked the network to inflammatory signaling and impaired barrier function. The team then searched drug-response databases for compounds predicted to reverse the patient’s gene activity patterns. Molecular simulations pointed to curcumin and evodiamine, and tests in cultured human lung cells found that curcumin preferentially stabilized MAPK8, while evodiamine modestly stabilized both MAPK8 and JAK2. To test the compounds in animals, the researchers began treatment before exposing mice to lipopolysaccharide, a component of the bacterium's outer membrane. They measured lung fluid accumulation, protein leakage into the airways, tissue damage and inflammatory markers. Both compounds reduced lung swelling and injury when given individually. Together, they reduced activation of both signaling pathways and brought two circulating inflammatory markers, interleukin-1 beta and tumor necrosis factor alpha, close to levels seen in control mice. Lung tissue from mice given the combination also showed fewer infiltrating macrophages and neutrophils. A separate experiment pairing inhibitors of the same pathways likewise reduced tissue damage, supporting the choice of MAPK8 and JAK2 as targets for further study.

The study links molecular changes observed during a patient's illness to two pathways that can be targeted to reduce acute lung injury in mice. The clinical data came from one patient, and the animal experiments tested a short-term inflammatory response to a bacterial component. Larger patient studies and animal studies involving live infection could clarify whether the approach can limit lung damage while preserving bacterial clearance. Further work will also need to establish how the compounds are absorbed and distributed, assess their safety and determine whether they can serve as starting points for drugs used alongside antibiotics.

###

References

DOI

10.48130/targetome-0026-0055

Original Source URL

https://doi.org/10.48130/targetome-0026-0055

Funding information

This work was supported by the National Natural Science Foundation of China (Grant Nos 82373931 and 82675099 to Wu X, 81774081 to Lu X, 82373882 to Yi H, and 82373884 to Du R), the Basic Research Program of Jiangsu (Grant No. BK20251992), and the Lingang Laboratory (Grant No. LGL-2612-12) to Wu X.

About Targetome

Targetome refers to the complete collection of molecular targets (e.g., proteins, RNA or DNA) that interact with and mediate the effect of a specific biomolecule, such as a drug, toxin, metabolites, transcription factor or microRNA, within a biological system. Targetome (Print ISSN 3071-0596; e-ISSN 3070-3808) is an open access journal publishing rigorously peer-reviewed original research articles, reviews, break-through methods, and perspectives that advance our understanding, identification and validation of molecular targets for new drug development.

Paper title: Dual targeting of MAPK8 and JAK2 as a host-directed anti-inflammatory strategy for severe Klebsiella pneumoniae infection
Archivos adjuntos
  • Longitudinal untargeted metabolomic profiling identifies taurine-driven host-microbiota co-metabolism as a hallmark signature of Klebsiella pneumoniae empyema.
16/11/2026 TranSpread
Regions: North America, United States, Asia, China
Keywords: Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement